Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $326.1K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +15 vs. previous quarter
- 45
- 13F valueReported value at the end of Q2 2026
- $333.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding FTH, Q2 2026
No superinvestor reported holding FTH at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Faeth Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)8:09 PM ET | Jun 29-Jul 1 | 2 days | Stephenson Brian CChief Financial Officer | PPurchase | +13.6K | $23.92 | +$326.1K | +41.2%46.7K after | 6 lots |
| Jun 26, 2026 (view filing) | Jun 24-26 | 2 days | Stephenson Brian CChief Financial Officer | PPurchase | +15.6K | $25.65 | +$401.3K | +89.8%33.1K after | 8 lots |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Parikh Anand KiranPresident and CEO | PPurchase | +2.81K | $19.76 | +$55.4K | +0.4%764.2K after | |
| Jun 24, 2026 (view filing) | Jun 22-23 | 2 days | Stephenson Brian CChief Financial Officer | PPurchase | +17.4K | $23.31 | +$405.9K | New position17.4K after | 8 lots |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Cambrian BioPharma Inc10% Owner | SSale | −25.0K | $20.02 | −$500.5K | −16.1%130.1K after | 2 lots |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Peyer James10% Owner, Other: See remarks below | SSale | −25.0K | $20.02 | −$500.5K | −16.1%130.1K after | 2 lots |
| May 15, 2026 (view filing)4:24 PM ET | Apr 2-7 | 43 daysLate | Englander Israel A and 3 others10% Owner | PPurchase | +4.21K | $33.54 | +$141.4K | +3.2%134.0K after | 5 lots |
| May 15, 2026 (view filing)4:24 PM ET | Apr 2-7 | 43 daysLate | Englander Israel A and 3 others10% Owner | SSale | −17.1K | $31.51 | −$538.1K | −11.3%134.0K after | 12 lots |
| May 15, 2026 (view filing)4:22 PM ET | Mar 31-Apr 1 | 45 daysLate | Englander Israel A and 3 others10% Owner | PPurchase | +12.2K | $31.37 | +$382.1K | +9.0%147.7K after | 10 lots |
| May 15, 2026 (view filing)4:22 PM ET | Mar 31-Apr 1 | 45 daysLate | Englander Israel A and 3 others10% Owner | SSale | −2.74K | $28.07 | −$76.9K | −1.8%147.7K after | 7 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Faeth Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,020,103 | $50.5M | 1.06% | +1,985,554+5,747.1% | Added |
| Avoro Capital Advisors LLC | 1,444,039 | $36.1M | 0.32% | +1,444,039 | New |
| Baker Bros. Advisors LP | 1,286,411 | $32.2M | 0.16% | +1,286,411 | New |
| Balyasny Asset Management LLC | 1,042,198 | $26.1M | 0.05% | +1,025,993+6,331.3% | Added |
| Vivo Capital, LLC | 722,020 | $18.1M | 1.65% | 00.0% | Unchanged |
| Logos Global Management LP | 722,020 | $18.1M | 0.78% | +692,020+2,306.7% | Added |
| Ra Capital Management, L.P. | 722,020 | $18.1M | 0.16% | +722,020 | New |
| Fairmount Funds Management LLC | 722,020 | $18.1M | 1.19% | +722,020 | New |
| Caligan Partners LP | 629,467 | $15.7M | 0.76% | +503,465+399.6% | Added |
| B Group, Inc. | 610,169 | $15.3M | 8.66% | +610,169 | New |